Integrated phenotype-genotype approach in diagnosis and classification of common central nervous system tumours.
diffuse glioma
glioblastoma
medulloblastoma
recent advances
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
pubmed:
2
3
2019
medline:
23
2
2020
entrez:
2
3
2019
Statut:
ppublish
Résumé
After nearly a century of histological classification of central nervous system tumours, the 2016 revised WHO classification has incorporated molecular features with clinical and prognostic relevance into brain tumour classification. In this review, we discuss the latest integrated phenotype-genotype approach to the most common intrinsic brain tumours in adults and children. The key genetic mutations and abnormalities, essential to the definition of these tumours, in line with the current WHO classification are described. Practical dilemmas, including 'difficult' tumours, the utility of DNA methylation classifiers and relevant recent advances post-WHO 2016 consensus are also discussed.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
299-311Subventions
Organisme : National Institute for Health Research
Organisme : Brain Tumour Research Charity
Organisme : Medical Research Council
ID : G0902001
Pays : United Kingdom
Organisme : Brain Tumour Charity
ID : GN-000389
Organisme : Medical Research Council
ID : MR/N000528/1
Pays : United Kingdom
Organisme : Barts Charity
Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
UK CR. Brain, other CNS and intracranial tumours incidence statistics: Cancer Research UK; 2017 [updated January 2018. Data obtained from the Office for National Statistics (July 2017); ISD Scotland (August); Welsh Cancer Intelligence and Surveillance Unit Health Intelligence Division, Public Health Wales (October); the Northern Ireland Cancer Registry (July). Data are for UK, 5, ICD-10 C70-C72, C75.1-C75.3, D32-D33, D35.2-D35.4, D42-D43, D44.3-D44.5.]. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/brain-other-cns-and-intracranial-tumours/incidence#heading-One. Date accessed 14 January 2019.
Louis DN, Ohgaki H, Wiestler OT, Cavenee WK. WHO classification of tumours of the central nervous system, revised 4th ed. Berlin/Heidelberg: Springer-Verlag, 2016.
Louis DN, Perry A, Reifenberger G et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016; 131; 803-820.
Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114; 97-109.
Reuss DE, Sahm F, Schrimpf D et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an ‘integrated’ diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2015; 129; 133-146.
Hartmann C, Meyer J, Balss J et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009; 118; 469-474.
Hattori N, Hirose Y, Sasaki H et al. World Health Organization grade II-III astrocytomas consist of genetically distinct tumor lineages. Cancer Sci. 2016; 107; 1159-1164.
Mullighan CG, Williams RT, Downing JR, Sherr CJ. Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev. 2008; 22; 1411-1415.
Shirahata M, Ono T, Stichel D et al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. 2018; 136; 153-166.
Brandner S, Jaunmuktane Z. IDH mutant astrocytoma: biomarkers for prognostic stratification and the next frontiers. Neuropathol. Appl. Neurobiol. 2018; 45; 91-94.
Sahm F, Reuss D, Koelsche C et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 2014; 128; 551-559.
Ostrom QT, Gittleman H, Liao P et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16(Suppl. 4); iv1-iv63.
Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin. Cancer Res. 2009; 15; 6002-6007.
Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009; 360; 765-773.
Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004; 64; 6892-6899.
Ellison DW, Kocak M, Figarella-Branger D et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J. Negat. Results Biomed. 2011; 10; 7.
Pajtler KW, Mack SC, Ramaswamy V et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol. 2017; 133; 5-12.
Pajtler KW, Witt H, Sill M et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 2015; 27; 728-743.
Garre ML, Cama A, Bagnasco F et al. Medulloblastoma variants: age-dependent occurrence and relation to Gorlin syndrome - a new clinical perspective. Clin. Cancer Res. 2009; 15; 2463-2471.
Cho YJ, Tsherniak A, Tamayo P et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J. Clin. Oncol. 2011; 29; 1424-1430.
Kool M, Koster J, Bunt J et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE 2008; 3; e3088.
Northcott PA, Korshunov A, Witt H et al. Medulloblastoma comprises four distinct molecular variants. J. Clin. Oncol. 2011; 29; 1408-1414.
Thompson MC, Fuller C, Hogg TL et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J. Clin. Oncol. 2006; 24; 1924-1931.
Taylor MD, Northcott PA, Korshunov A et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012; 123; 465-472.
Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene 2017; 36; 1461-1473.
Zhukova N, Ramaswamy V, Remke M et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J. Clin. Oncol. 2013; 31; 2927-2935.
Huang H, Mahler-Araujo BM, Sankila A et al. APC mutations in sporadic medulloblastomas. Am. J. Pathol. 2000; 156; 433-437.
Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW. Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers (Basel) 2016; 8; 22.
Northcott PA, Shih DJ, Peacock J et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012; 488; 49-56.
Ellison DW, Dalton J, Kocak M et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011; 121; 381-396.
Rudin CM, Hann CL, Laterra J et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 2009; 361; 1173-1178.
Yauch RL, Dijkgraaf GJ, Alicke B et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009; 326; 572-574.
Northcott PA, Lee C, Zichner T et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature 2014; 511; 428-434.
Shih DJ, Northcott PA, Remke M et al. Cytogenetic prognostication within medulloblastoma subgroups. J. Clin. Oncol. 2014; 32; 886-896.
Schwalbe EC, Lindsey JC, Nakjang S et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol. 2017; 18; 958-971.
Besingi W, Johansson A. Smoke-related DNA methylation changes in the etiology of human disease. Hum. Mol. Genet. 2014; 23; 2290-2297.
Sturm D, Witt H, Hovestadt V et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012; 22; 425-437.
Thomas C, Sill M, Ruland V et al. Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. Neuro Oncol. 2016; 18; 790-796.
Wiestler B, Capper D, Sill M et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 2014; 128; 561-571.
Capper D, Jones DTW, Sill M et al. DNA methylation-based classification of central nervous system tumours. Nature 2018; 555; 469-474.